PAVING THE WAY FOR ASSESSING IN VIVO DYNAMICS OF MULTIPLE QUALITY ATTRIBUTES FOR PROTEIN THERAPEUTICS
|
|
- Blaze Andrews
- 6 years ago
- Views:
Transcription
1 PAVING THE WAY FOR ASSESSING IN VIVO DYNAMICS OF MULTIPLE QUALITY ATTRIBUTES FOR PROTEIN THERAPEUTICS CASSS Mass Spec September 21, 2017 Haihong Zhou Principal Scientist, Biologics, Vaccines & Bioanalytics PPDM Merck & Co., Inc., Kenilworth, NJ, USA 1
2 Outline Workflow for measuring multiple quality attributes in vivo Key drivers Challenges Method development considerations Proof of concept studies Differential Analysis 2
3 In Vivo Dynamics of Quality Attributes: Bioanalytical Multi-Attribute Method In Vivo Dosing Drug (antibody, fusion protein, peptide, nanobody, etc) Background protein Blood Collection Attribute Time (min) Affinity Purification Elution/Digestion High-resolution LC/MS Characterization Relative Abundance Impact of PQAs on product safety and efficacy mab Concentration mab PK Profile X Proportion with Attribute = Proportion of mab with Attribute X = Time In Vivo Attribute Exposure Profile Attribute Concentration Differential Analysis Peptide Identification Attribute Identification and Quantification Adapted from Goetze AM, et al. MAbs. 2010;Sep-Oct;2(5): ; Li Y, et al. MAbs. 2016;Aug-Sep;8(6):
4 Key Drivers Help evaluate criticality of the quality attributes and facilitate manufacturing process development Assess the effect of product quality attributes on safety and efficacy Establish better understanding of PK/PD relationship 4
5 Challenges in Quantifying Multiple Quality Attributes In Vivo Bioanalytical MAM Bioanalytical MAM Determine drug concentration (PK) In Vivo Limited volume Low concentration Complex matrix May need purification LC/MS QQQ Simple processing steps (Monitor one or two peptides) - Absolute quantitation - High throughput - Known Detect changes in multiattributes in vitro (CMC) In Vitro Volume not limited High concentration Buffer No need for purification LC/MS High Resolution Complex processing steps (Monitor all peptides) - Relative quantitation - Low throughput - Known & unknown Detect changes in multiattributes in vivo (metabolism) In Vivo Limited volume Low concentration Complex matrix Require purification LC/MS High Resolution Complex processing steps (Monitor all peptides) - Relative quantitation - Low throughput - Known & unknown 5
6 Proof of Concept Using an IgG1 mab Starting point: CMC MAM Drug in Buffer Direct analysis Drug in Buffer Immuno-enrichment Control for sample processing induced modifications Drug Spiked in Serum Immuno-enrichment Drug in Serum ex vivo Immuno-enrichment Drug in Serum in vivo Immuno-enrichment 6
7 Method Development Considerations Sensitivity requirement Concentrations in PK profile Available sample volume Affinity purification Choice of the capture antibody Affinity purification media (binding capacity, nonspecific binding, ease of automation, etc.) Optimization on yield and purity Digestion conditions Choice of protease LC/MS instrumentation Low flow vs high flow chromatography Low resolution vs high resolution mass spectrometer Overall method reproducibility 7
8 Method Performance Reproducibility Sequence coverage Control for sample processing induced modifications Relative Intensity Heavy Chain 3 Leader Sequence 2 Light Chain 4 Unidentified RT (min)
9 Controls HC D222 IsoD HC M429 Oxidation 40 8 % Attribute % Attribute Ref. Material #1 Ref. Material #2 12M25C #1 12M25C #2 0 0 % Attribute Direct Digestion (100 µg) Direct Digestion (15 µg) IP from Serum (15 µg) HC N385 & N390 Deamidation Direct Digestion (100 µg) Direct Digestion (15 µg) IP from Serum (15 µg) % Attribute Direct Digestion (100 µg) Direct Digestion (100 µg) Direct Digestion (15 µg) LC pe Direct Digestion (15 µg) IP from Serum (15 µg) IP from Serum (15 µg) Consistent recovery of all the quality attributes with and without affinity purification and with different digestion methods indicates that 1. There was no bias in the affinity purification step toward any specific quality attribute 2. Overall sample processing procedure did not alter quality attributes 9
10 Bioanalytical MAM Study Design In Vivo IV infusion at 200 mg/kg Predose D0 (0.5hr) D2 D4 D7 Ex Vivo 0.5 mg/ml spiked in cynomolgus monkey serum; incubate at 37 C D0 D2 D4 D7 10
11 N-terminal Modification: HC Glutamine to Pyro-glutamate A complete conversion of N-terminal glutamine residue into N-terminal pyroglutamate was observed in vivo In Vivo Ex Vivo Relative Percentage (%) Cyno-1 Cyno-2 Cyno-3 Relative Percentage (%) Replicate 1 Replicate 2 Replicate Relative Percentage (%) = PPPP AAAA (PPPPPPP mmmm) PPPP AAAA PPPPPPP mmmm +PPPP AAAA PPPPPPP mmmm +PPPP AAAA (PPPPPPP uuuuu) 11
12 Deamidation: HC N385/N390 A conserved site in the Fc domain commonly found in humanized monoclonal antibodies exhibited a rapid increase in deamidation In Vivo Ex Vivo Relative Percentage (%) Cyno-1 Cyno-2 Cyno-3 Relative Percentage (%) Replicate 1 Replicate 2 Replicate Deamidation Rate: In vivo: 0.9%/day (1.1% 1 ) Ex vivo: 1.5%/day (1.7% 1 ) 1 Yin S, et al. Pharm Res. 2013;30:
13 C-terminal Modification: HC Lysine Processing C-terminal lysine processing was likely due to carboxypeptidase activity In Vivo Ex Vivo Relative Percentage (%) Cyno-1 Cyno-2 Cyno-3 Relative Percentage (%) Replicate 1 Replicate 2 Replicate
14 High-mannose Glycans High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance Relative Percentage (%) Man5 Relative Percentage (%) Man6 Man7 Man8 Relative Percentage (%) A2G0F A2G1F
15 Example of Attribute Exposure Profile HC N385 & N390 Deamidation 8000 PK Profile 8 % Attribute 160 Attribute Exposure Profile Serum Concentration (µg/ml) Relative Percentage (%) Serum Concentration (µg/ml) Cyno-1 Cyno-2 Cyno
16 Looking for Unknown Changes in an Unbiased Manner Ex Vivo Day 0 Ex Vivo Day 7 Monkey Serum Affinity Purification LC/MS/MS Differential Analysis Identification SIEVE (ThermoFisher) BioPharma Finder (ThermoFisher) Progenesis QI (Waters-Nonlinear Dynamics) Quantification 16
17 SIEVE Ex Vivo Day 0 vs Ex Vivo Day 7 SIEVE was able to pick up most of the known changes in the sample 12.0 Ex Vivo Relative Percentage Replicate 1 Replicate 2 Replicate Time (Day) Deamidation HC N385/N390 17
18 SIEVE (continued) Relative Abundance HC76-86 Deamidation NL: 5.74E4 Base Peak m/z= F: FTMS + p ESI Full ms [ ] MS _cyno_D0_1 NL: 2.10E5 Base Peak m/z= F: FTMS + p ESI Full ms [ ] MS _cyno_d7_1 Low abundant deamidation was missed by SIEVE with threshold of 1e6 Lower threshold (eg, 1e4) allowed SIEVE to detect HC76-86 deamidation. However, more false positives were observed when using lower threshold Time (min) 18
19 BioPharma Finder Low abundant attribute changes were detected, and the percent attribute was calculated automatically 19
20 Progenesis QI Low abundant HC76-86 deamidation was also detected using Progenesis D0 D7 Deamidated Intensity Unmodified Intensity 20
21 Differential Analysis for Bioanalytical MAM All three algorithms can pick up known attribute changes BioPharma Finder has better identification capability and calculates attribute percentage automatically when peptide identity is known Challenges for all three algorithms include: Setting up the appropriate threshold to minimize the number of false positives Statistical analysis tools to help reduce false positives Filtering strategies and visualization tools to help distinguish false positives from true positives The ability to normalize overall intensity, align retention time, and perform peak picking when molecule concentration differs several folds across multiple time points 21
22 Summary We demonstrate that it is feasible to track changes in multiple quality attributes for a IgG1 monoclonal antibody in cynomologus monkey serum We present a general strategy on how to identify and quantify changes in multiple quality attributes of protein therapeutics in vivo Further developmental efforts are needed to improve Overall sample processing sensitivity and reproducibility Algorithms for differential analysis can be modified to streamline the data analysis workflow (eg, comparison with multiple time points and better visualization tools) 22
23 Acknowledgments Merck & Co., Inc. Yi Wang, Douglas Richardson, Bhumit Patel, Daniela Tomazela, Vibha Jawa, Richard Wong, Dong Hun Lee, Sejal Patel, Maribel Beaumont, Yan-hui Liu, Ayesha Sitlani, David Pollard, Shuangping Shi, Hetal Sarvaiya, Amy Beebe, Yaoli Song, Mohammad Tabrizifard, David McLaren, Stephen Previs, Maria Webb, Xiang Yu Just Biotherapeutics Richard Rogers ThermoFisher Michael Blank, Jennifer Sutton Rockefeller University Yinyin Li 23
Advanced QA/QC characterization MS in QC : Multi Attribute Method
Advanced QA/QC characterization MS in QC : Multi Attribute Method Global BioPharma Summit The world leader in serving science A Complex Problem: Drug Safety and Quality Safety Is the product safe to use?
More informationDeveloping Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus
Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus Robert Birdsall, Thomas Wheat, and Weibin Chen Waters Corporation,
More informationPharmacokinetic Analysis of the mab Adalimumab by ELISA and Hybrid LBA/LC/MS: A Comparison Study
Pharmacokinetic Analysis of the mab Adalimumab by ELISA and Hybrid LBA/LC/MS: A Comparison Study Featuring the SCIEX BioBA Solution Xi Qu 1, Shuyu Hou 1, Meghan McCann 1, Caroline Becker 1, Xun Wang 1,
More informationModern Analytics for Biologics: Platforms, Multi-Attribute Methods and Real-Time Release
Modern Analytics for Biologics: Platforms, Multi-Attribute Methods and Real-Time Release Dr. Corné J.M Stroop MMD, Director Method Development, Characterization & Process Support Dr. Hans-Martin Mueller
More informationRapidly Characterize Antibody- Drug Conjugates and Derive Drug-to-Antibody Ratios Using LC/MS
Rapidly Characterize Antibody- Drug Conjugates and Derive Drug-to-Antibody Ratios Using LC/MS Ning Tang, Ph.D. Agilent Technologies Santa Clara, California, USA Heterogeneity in ADCs Complexity T-DM1 (Genentech)
More informationLeveraging the MAM to Improve Biotherapeutic Characterization Rich Rogers
Leveraging the MAM to Improve Biotherapeutic Characterization Rich Rogers Successful characterization of a Biotherapeutic requires 3 components 1. High-resolution/High-mass accuracy mass spec 2. Accurate
More informationWhat s the difference? Challenges in pre-clinical development of biologics
Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31
More informationWhy do LC MS and LBA
Why do LC MS and LBA results differ? A literature evaluation 18 November 2015 Nico van de Merbel An overview In most published BA methods for large molecules, no comparison of platforms (LBA vs LBA, LBA
More informationXevo G2-S QTof and TransOmics: A Multi-Omics System for the Differential LC/MS Analysis of Proteins, Metabolites, and Lipids
Xevo G2-S QTof and TransOmics: A Multi-Omics System for the Differential LC/MS Analysis of Proteins, Metabolites, and Lipids Ian Edwards, Jayne Kirk, and Joanne Williams Waters Corporation, Manchester,
More informationApplication of a Mass Spectrometry Based Multi-Attribute-Method (MAM) for QC Release and Stability Testing of Protein Therapeutics
Application of a Mass Spectrometry Based Multi-Attribute-Method (MAM) for QC Release and Stability Testing of Protein Therapeutics Tamer Eris, Principal Scientist Process Development Amgen, Thousand Oaks,
More informationLabChip GXII: Antibody Analysis
WHITE PAPER LabChip GXII: Antibody Analysis Antibody Analysis using microfluidic technology in high throughput Quality by Design Experiments Abstract Current initiatives in Process Analytical Technology
More informationCritical Quality Attributes for Biotechnology Products: A Regulatory Perspective
Critical Quality Attributes for Biotechnology Products: A Regulatory Perspective Patrick G. Swann, Ph.D. Deputy Director Division of Monoclonal Antibodies Office of Biotechnology Products Office of Pharmaceutical
More informationmabs and ADCs analysis by RP
mabs and ADCs analysis by RP Shanhua Lin, Ph.D. The world leader in serving science Protein and mab Separation by HPLC Size difference? YES Size Exclusion Chromatography (SEC) MAbPac SEC-1 NO NO Charge
More informationRapid Peptide Catabolite ID using the SCIEX Routine Biotransform Solution
Rapid Peptide Catabolite ID using the SCIEX Routine Biotransform Solution Rapidly Identify Major Catabolites with the SCIEX X500R QTOF System and MetabolitePilot TM 2.0 Software Ian Moore and Jinal Patel
More informationJürgen Fichtl, Development Characterization Pharma Technical Development, Penzberg, Germany Mass Spec 2013, September 23-26, Boston
Analytical Strategies for Assessment of Disulfide Linkages in Biopharmaceuticals Jürgen Fichtl, Development Characterization Pharma Technical Development, Penzberg, Germany Mass Spec 2013, September 23-26,
More informationApplication Note. Kwasi Antwi, Amanda Ribar, Urban A. Kiernan, and Eric E. Niederkofler Thermo Fisher Scientific, Tempe, Arizona
Analysis of an Antibody Drug Conjugate using MSIA D.A.R.T. S. Technology, an Integral Part of Ligand Binding Mass Spectrometric Immunoassay (LB-MSIA) Workflow Application Note Kwasi Antwi, Amanda Ribar,
More informationAnalysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb 5 µm Column
Analysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb µm Column Application Note BioPharma Authors Xiaomi Xu and Phu T Duong Agilent Technologies, Inc. Abstract Nearly all proteins undergo
More informationN-Glycan Profiling Analysis of a Monoclonal Antibody Using UHPLC/FLD/Q-TOF
N-Glycan Profiling Analysis of a Monoclonal Antibody Using UHPLC/FLD/Q-TOF Application Note Authors Xianming Liu, Wei Zhang, Yi Du, Sheng Yin, Hong Que, and Weichang Zhou WuXi AppTec iopharmaceuticals
More informationPrecise Characterization of Intact Monoclonal Antibodies by the Agilent 6545XT AdvanceBio LC/Q-TOF
Precise Characterization of Intact Monoclonal Antibodies by the Agilent 6545XT AdvanceBio LC/Q-TOF Application Note Author David L. Wong Agilent Technologies, Inc. Santa Clara, CA, USA Introduction Monoclonal
More informationAntibody Analysis by ESI-TOF LC/MS
Application Note PROTEOMICS METABOLOMICS GENOMICS INFORMATICS GLYILEVALCYSGLUGLNALASERLEUASPARG CYSVALLYSPROLYSPHETYRTHRLEUHISLYS Antibody Analysis by ESI-TOF LC/MS Authors Lorenzo Chen, Merck & Company,
More informationApplication Note. Author. Abstract. Biopharmaceuticals. Verified for Agilent 1260 Infinity II LC Bio-inert System. Sonja Schneider
Combining small-scale purification and analysis of monoclonal antibodies on one instrument Protein purification with high-volume injection using the Agilent 126 Infinity Bio-inert Quaternary LC System
More informationA Unique LC-MS Assay for Host Cell Proteins(HCPs) ) in Biologics
A Unique LC-MS Assay for Host Cell Proteins(HCPs) ) in Biologics Catalin Doneanu,, Ph.D. Biopharmaceutical Sciences, Waters September 16, 2009 Mass Spec 2009 2009 Waters Corporation Host Cell Proteins
More informationCurrent practice and future vision on metabolite profiling and quantification in Drug development
Current practice and future vision on metabolite profiling and quantification in Drug development Geert Mannens EBF Focus workshop Metabolite Profiling and Quantification Strategies in Drug R&D Sept 25,
More informationThermo Scientific Peptide Mapping Workflows. Upgrade Your Maps. Fast, confident and more reliable peptide mapping.
Thermo Scientific Peptide Mapping Workflows Upgrade Your Maps Fast, confident and more reliable peptide mapping. Smarter Navigation... Peptide mapping is a core analytic in biotherapeutic development.
More informationTony Mire-Sluis Vice President, Corporate, Product and Device Quality Amgen Inc
The Regulatory Implications of the ever increasing power of Mass Spectrometry and its role in the Analysis of Biotechnology Products Where do we draw the line? Tony Mire-Sluis Vice President, Corporate,
More informationDesign and Validation of a Non Cell-based Receptor Binding Assay for the Detection of Neutralizing Antibodies to a Biological Therapeutic
Design and Validation of a Non Cell-based Receptor Binding Assay for the Detection of Neutralizing Antibodies to a Biological Therapeutic Shalini Gupta Associate Director Amgen, Thousand Oaks, CA shalinig@amgen.com
More informationMaximizing Chromatographic Resolution of Peptide Maps using UPLC with Tandem Columns
Maximizing Chromatographic Resolution of Peptide Maps using UPLC with Tandem Columns Hongwei Xie, Martin Gilar, and Jeff Mazzeo Waters Corporation, Milford, MA U.S. APPLICATION BENEFITS The ACQUITY UPLC
More informationAsish Chakraborty, St John Skilton, Weibin Chen and John C. Gebler Waters Corporation, Milford, MA, U.S. INTRODUCTION METHODS. Sample preparation
Com p r e h ensiv e a n d Rou t in e C ha r ac t e riz at io n o f P rot eins a n d P e p t i d e s by LC/MS and LC/MS E Asish Chakraborty, St John Skilton, Weibin Chen and John C. Gebler Waters Corporation,
More informationPLRP-S Polymeric Reversed-Phase Column for LC/MS Separation of mabs and ADC
PLRP-S Polymeric Reversed-Phase Column for LC/MS Separation of mabs and ADC Analysis of Intact and Fragmented mabs and ADC Application Note Biotherapeutics and Biologics Author Suresh Babu C.V. Agilent
More informationProteins. Patrick Boyce Biopharmaceutical Marketing Manager Waters Corporation 1
Routine Characterization of mabs and Other Proteins Patrick Boyce Biopharmaceutical Marketing Manager Europe and India 2011 Waters Corporation 1 Agenda Why? What scientific challenges? Technology Example
More informationProteomics And Cancer Biomarker Discovery. Dr. Zahid Khan Institute of chemical Sciences (ICS) University of Peshawar. Overview. Cancer.
Proteomics And Cancer Biomarker Discovery Dr. Zahid Khan Institute of chemical Sciences (ICS) University of Peshawar Overview Proteomics Cancer Aims Tools Data Base search Challenges Summary 1 Overview
More informationIdentification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy
Identification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy Ziping Wei, Ph.D. Analytical Biochemistry MedImmune January 25, 2010 Outline Why do we need to identify
More informationDevelopment of Analysis Methods for Therapeutic Monoclonal Antibodies Using Innovative Superficially Porous Particle Biocolumns
Development of Analysis Methods for Therapeutic Monoclonal Antibodies Using Innovative Superficially Porous Particle Biocolumns Anne Blackwell Bio Columns Product Support Scientist Suresh Babu Senior Application
More informationMonoclonal Antibody Characterization on Q Exactive and Oribtrap Elite. Yi Zhang, Ph.D Senior Proteomic Marketing Specialist Oct.
Monoclonal Antibody Characterization on Q Exactive and Oribtrap Elite Yi Zhang, Ph.D Senior Proteomic Marketing Specialist Oct. 12, 211 Outline Orbitrap Mass Spectrometer in mab Characterization Intact
More informationSMART Digest Kit User Manual. Version 2
SMART Digest Kit User Manual Version 2 XX21543 Revision A August 2016 SMART Digest Kit Delivering simple, fast and reproducible digestion of proteins Thermo Scientific SMART Digest kits are designed for
More informationDisulfide Linkage Analysis of IgG1 using an Agilent 1260 Infinity Bio inert LC System with an Agilent ZORBAX RRHD Diphenyl sub 2 µm Column
Disulfide Linkage Analysis of IgG1 using an Agilent 126 Infinity Bio inert LC System with an Agilent ZORBAX RRHD Diphenyl sub 2 µm Column Application Note Biotherapeutics & Biosimilars Author M. Sundaram
More informationBiosimilars Scientific Challenges and Implications
Biosimilars Scientific Challenges and Implications Professor Paul Declerck Laboratory for Therapeutic and Diagnostic Antibodies paul.declerck@pharm.kuleuven.be Biological medicinal product A well-defined
More informationRecent Advancements in Analytical Methods of Drug Detection
Recent Advancements in Analytical Methods of Drug Detection Mario Thevis Gene and Cell Doping Symposium Beijing, June 5/6, 2013 www.wada-ama.org Challenges at the time accepted by anti-doping authorities
More informationUtilizing novel technology for the analysis of therapeutic antibodies and host cell protein contamination
Utilizing novel technology for the analysis of therapeutic antibodies and host cell protein contamination Kelli Jonakin, Ph.D. Senior Field Application Scientist, Seattle, WA Eric Johansen, Ph.D. Senior
More informationphab Amine and Thiol Reactive Dyes for Antibody Internalization Studies Nidhi Nath, Ph.D. Group Leader, Protein Analysis Promega Corporation
phab Amine and Thiol Reactive Dyes for Antibody Internalization Studies Nidhi Nath, Ph.D. Group Leader, Protein Analysis 1 Outline 1. phab Dyes 2. Protocols for conjugating phab Dyes to antibodies 3. Applications:
More informationSMART Digest compared to classic in-solution digestion of rituximab for in-depth peptide mapping characterization
APPLICATION NOTE Digest compared to classic in-solution digestion of rituximab for in-depth peptide mapping characterization No. 1159 Authors: Martin Samonig 1, Alexander Schwahn 2, Ken Cook 3, Mike Oliver
More informationHighly Confident Peptide Mapping of Protein Digests Using Agilent LC/Q TOFs
Technical Overview Highly Confident Peptide Mapping of Protein Digests Using Agilent LC/Q TOFs Authors Stephen Madden, Crystal Cody, and Jungkap Park Agilent Technologies, Inc. Santa Clara, California,
More informationParadigm Shift in Comparability Assessment:
Paradigm Shift in Comparability Assessment: How Quality by Design (QbD) and Process Analytical Technology (PAT) can improve Structure-Activity Relationship (SAR) evaluation and its relevance to comparability
More informationHigh-Throughput Peptide Mapping with the Vanquish UHPLC System and the Q Exactive HF Mass Spectrometer
High-Throughput Peptide Mapping with the Vanquish UHPLC System and the Q Exactive HF Mass Spectrometer Martin Samonig 1, Kai Scheffler 2, Remco Swart 1, and Jonathan Josephs 3 1 Thermo Fisher Scientific,
More informationMagSi Beads. Magnetic Silica Beads for Life Science and Biotechnology study
MagSi Beads Magnetic Silica Beads for Life Science and Biotechnology study MagnaMedics Diagnostics B.V. / Rev. 9.2 / 2012 Wide range of products for numerous applications MagnaMedics separation solutions
More informationMonoclonal Antibody Charge Variants: Origins, Physicochemical Characterization, and Pharmacokinetics
Monoclonal Antibody Charge Variants: Origins, Physicochemical Characterization, and Pharmacokinetics Paul Motchnik Protein Analytical Chemistry Genentech, South San Francisco, CA January 10, 2011 Washington,
More informationPeptide Mapping: A Quality by Design (QbD) Approach
Peptide Mapping: A Quality by Design (QbD) Approach Application Note Bio-Pharmaceutical Authors Sreelakshmy Menon and Suresh babu C.V. Agilent Technologies, Inc. Richard Verseput S-Matrix Corporation Abstract
More informationApplication Note. Authors. Abstract
Automated, High Precision Tryptic Digestion and SISCAPA-MS Quantification of Human Plasma Proteins Using the Agilent Bravo Automated Liquid Handling Platform Application Note Authors Morteza Razavi, N.
More informationUNIFI: an innovative enabling platform Ken Eglinton Nordic User Training, September 2013
UNIFI: an innovative enabling platform Ken Eglinton Nordic User Training, September 2013 2013 Waters Corporation 1 Waters Laboratory Informatics Product Portfolio MassLynx Mass Spectrometry Software NuGenesis
More informationComparability Assessment of BioTherapeutics: Paving the Way for Late-Stage Projects
Comparability Assessment of BioTherapeutics: Paving the Way for Late-Stage Projects Olga Friese, PhD Associate Research Fellow Pfizer Biotherapeutics PharmSci 28 January 2014 Overview Manufacturing process
More informationDevelopment of Multiplex Sensitive Anti-Drug Antibody Assays for CRISPR/Cas9 Gene Therapies
Development of Multiplex Sensitive Anti-Drug Antibody Assays for CRISPR/Cas9 Gene Therapies September 27, 2017 Junxia Wang editasmedicine.com 1 Overview of the presentation Immunogenicity Introduction
More informationProgenesis QI for proteomics: a first-rate solution for relative and absolute quantitative workflows Richard R. Sprenger, PhD
Progenesis QI for proteomics: a first-rate solution for relative and absolute quantitative workflows Richard R. Sprenger, PhD Lipid Research Group Institute for Biochemistry and Molecular Biology University
More informationIntelligent Disulfide Bond Analysis
Intelligent Disulfide Bond Analysis Why Study Disulfide Bonds? Save Money by making cell cultures more efficient! Regulations Process Control Higher Quality biotherapeutics Efficacy Protect from Competition
More informationApplication Note. Author. Abstract. Biotherapeutics and Biologics. Sonja Schneider Agilent Technologies, Inc. Waldbronn, Germany
D-LC/MS Characterization of Charge Variants Using Ion Exchange and Reversed-Phase Chromatography Multiple Heart-Cutting D-LC Analysis of Innovator versus Biosimilar Monoclonal Antibodies Application Note
More informationRevised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion
Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion Robin Thorpe & Meenu Wadhwa Revised Guideline: Differences from original
More informationA Complete Workflow Solution for Intact Monoclonal Antibody Characterization Using a New High-Performance Benchtop Quadrupole- Orbitrap LC-MS/MS
A Complete Workflow Solution for Intact Monoclonal Antibody Characterization Using a New High-Performance Benchtop Quadrupole- Orbitrap LC-MS/MS Zhiqi Hao, 1 Yi Zhang, 1 David Horn, 1 Seema Sharma, 1 Shiaw-Lin
More informationAntibody-drug Conjugates: Characterization and Control Strategies of Lysine-linked Products
Antibody-drug Conjugates: Characterization and Control Strategies of Lysine-linked Products Fred Jacobson Protein Analytical Chemistry Genentech, Inc. CASSS CMC Strategy Forum Japan 2013 December 9-10,
More informationmab Titer Analysis with the Agilent Bio-Monolith Protein A Column
mab Titer Analysis with the Agilent Bio-Monolith Protein A Column Application Note Biopharmaceuticals and Biosimilars Authors Emmie Dumont, Isabel Vandenheede, Pat Sandra, and Koen Sandra Research Institute
More informationMBios 478: Mass Spectrometry Applications [Dr. Wyrick] Slide #1. Lecture 25: Mass Spectrometry Applications
MBios 478: Mass Spectrometry Applications [Dr. Wyrick] Slide #1 Lecture 25: Mass Spectrometry Applications Measuring Protein Abundance o ICAT o DIGE Identifying Post-Translational Modifications Protein-protein
More informationAntibody-Drug Conjugate Bioanalytical Assay Development:
Antibody-Drug Conjugate Bioanalytical Assay Development: Immunogenicity Challenges November 16, 2016 Presented by Corinna Fiorotti, Ph.D. Presentation Overview ADC Overview ADC Assays ADC Immunogenicity
More informationThermo Scientific Solutions for Intact-Protein Analysis. Better, Faster Decisions for. Biotherapeutic Development
Thermo Scientific Solutions for Intact-Protein Analysis Better, Faster Decisions for Biotherapeutic Development Quickly and Accurately Assess Product Quality and Safety Therapeutic proteins and monoclonal
More informationKey Words Q Exactive Focus, SIEVE Software, Biomarker, Discovery, Metabolomics
Metabolomic Profiling in Drug Discovery: Understanding the Factors that Influence a Metabolomics Study and Strategies to Reduce Biochemical and Chemical Noise Mark Sanders 1, Serhiy Hnatyshyn 2, Don Robertson
More informationReference Standards: Overview and Strategy for Development to Commercialization
Reference Standards: Overview and Strategy for Development to Commercialization John Ruesch Analytical Research and Development CASSS / WCBP CMC Strategy Forum: Reference Standards For Therapeutic Proteins
More informationGenerating Automated and Efficient LC/MS Peptide Mapping Results with the Biopharmaceutical Platform Solution with UNIFI
with the Biopharmaceutical Platform Solution with UNIFI Vera B. Ivleva, Ying Qing Yu, Scott Berger, and Weibin Chen Waters Corporation, Milford, MA, USA A P P L I C AT ION B E N E F I T S The ability to
More informationRecombinant Antibody Production in Therapeutic Antibody Projects. Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016
Recombinant Antibody Production in Therapeutic Antibody Projects Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016 Presentation Outline 1 2 3 4 5 Introduction Recombinant Ab Production
More informationFPO. BioPharma Compass 2.0. Innovation with Integrity. Accelerate Biopharmaceutical Analysis. Software
FPO BioPharma Compass 2.0 Accelerate Biopharmaceutical Analysis Innovation with Integrity Software Developed with the Biopharma Industry Award-winning biopharmaceutical analysis platform Commercial and
More informationAdvantages of Ion Mobility QTOF for Characterization of BioPharma Molecules
Advantages of Ion Mobility QTOF for Characterization of BioPharma Molecules Add a New Dimension to your Research Capability with Agilent s New Drift Ion Mobility QTOF System David Wong, Ph.D. Sr. Application
More informationCRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES
CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES DELAWARE VALLEY DRUG METABOLISM DISCUSSION GROUP STEVE PICCOLI, BMS RAND JENKINS,
More informationCapillary Electrophoresis Compendial Applications
Capillary Electrophoresis Compendial Applications Anita Szajek, Ph.D. Principal Scientific Liaison, Biologics & Biotechnology 14 th Symposium on the Practical Applications for the Analysis of Proteins,
More informationCharacterization of Glycosylation in the Fc Region of Therapeutic Recombinant Monoclonal Antibody
Characterization of Glycosylation in the Fc Region of Therapeutic Recombinant Monoclonal Antibody Application Note BioPharma Authors James Martosella, Phu Duong, and Alex Zhu Agilent Technologies, Inc.
More informationENCODE DCC Antibody Validation Document
ENCODE DCC Antibody Validation Document Date of Submission 06/15/2012 Name: Trupti Kawli Email: trupti@stanford.edu Lab Snyder Antibody Name: CDP (sc6327) Target: CDP Company/ Source: Santa Cruz Catalog
More informationIgG Purity/Heterogeneity and SDS-MW Assays with High- Speed Separation Method and High Throughput Tray Setup
IgG Purity/Heterogeneity and SDS-MW Assays with High- Speed Separation Method and High Throughput Tray Setup High Throughput Methods to Maximize the Use of the PA 800 Plus system Jose-Luis Gallegos-Perez
More informationOvercoming drug & target interference in ADA and nabassays
Overcoming drug & target interference in ADA and nabassays Robert Nelson Ph.D. MRQA Head of Bioanalytical Laboratory, Novimmune SA 1 Presentation Outline Case Study 1 Drug & target interference in a clinical
More informationProtein stability assessment after automated buffer exchange
pplication Note Protein stability assessment after automated buffer exchange Introduction uffer preparation, exchange and sample concentration for a formulation screen can take 2 4 days of a scientist
More informationQuantify protein stability with ΔG
Technical Note Quantify protein stability with ΔG Introduction Biologics stability determinations often rely on forced degradation methods to rank constructs or optimize formulations. The most well-established
More informationA comparison of automated and manual buffer exchange methods
pplication Note comparison of automated and manual buffer exchange methods Introduction uffer preparation, exchange and sample concentration for a formulation screen can take 2 4 days of a scientist s
More informationConjugated protein biotherapeutics
B i o P r o c e s s TECHNICAL Mass Spectrometric Conjugate Characterization Process Qualification of Recombinant Protein Hapten Conjugation Miao-Fang Lin, Margo Wilson, Michael V. Murray, and Greg W. Adams
More informationCharacterize Fab and Fc Fragments by Cation-Exchange Chromatography
Characterize Fab and Fc Fragments by Cation-Exchange Chromatography Application Note Biologics and Biosimilars Authors Isabel Vandenheede, Emmie Dumont, Pat Sandra, and Koen Sandra Research Institute for
More informationThermo Scientific BioLC Columns. Monoclonal antibody. characterization
Thermo Scientific BioLC Columns Monoclonal antibody characterization Innovative technologies and workflows for increasing productivity and throughput Table of Contents Characterization of Monoclonal Antibodies
More informationComparability to establish Biosimilarity
Comparability to establish Biosimilarity CMC Strategy Forum Europe 2014, Sorrento, Italy Jan Visser, Head Global Analytical Characterization & Bioanalytics Sandoz Biopharmaceuticals, Hexal AG, Germany
More informationENCODE DCC Antibody Validation Document
ENCODE DCC Antibody Validation Document Date of Submission 09/12/12 Name: Trupti Kawli Email: trupti@stanford.edu Lab Snyder Antibody Name: SREBP1 (sc-8984) Target: SREBP1 Company/ Source: Santa Cruz Biotechnology
More informationProtein Purification Products. Complete Solutions for All of Your Protein Purification Applications
Protein Purification Products Complete Solutions for All of Your Protein Purification Applications FLAG-Tagged Protein Products EXPRESS with the pcmv-dykddddk Vector Set Fuse your protein of interest to
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationAgilent AdvanceBio SEC Columns for Aggregate Analysis: Instrument Compatibility
Agilent AdvanceBio SEC Columns for Aggregate Analysis: Instrument Compatibility Technical Overview Introduction Agilent AdvanceBio SEC columns are a new family of size exclusion chromatography (SEC) columns
More informationRapid Peptide Mapping via Automated Integration of On-line Digestion, Separation and Mass Spectrometry for the Analysis of Therapeutic Proteins
Rapid Peptide Mapping via Automated Integration of On-line Digestion, Separation and Mass Spectrometry for the Analysis of Therapeutic Proteins Esther Lewis, 1 Kevin Meyer, 2 Zhiqi Hao, 1 Nick Herold,
More informationFast Trak Services: a collaborative project to accelerate downstream biosimilar process development
GE Healthcare Fast Trak Services: a collaborative project to accelerate downstream biosimilar process development A case study Case study, 2924332 AA Fast Trak Services A collaborative project to accelerate
More informationAlgorithm for Matching Additional Spectra
Improved Methods for Comprehensive Sample Analysis Using Protein Prospector Peter R. Baker 1, Katalin F. Medzihradszky 1 and Alma L. Burlingame 1 1 Mass Spectrometry Facility, Dept. of Pharmaceutical Chemistry,
More informationAnalysis of biomolecules by SEC and Ion-Exchange UPLC
Analysis of biomolecules by SEC and Ion-Exchange UPLC Anders Feldthus, Waters Nordic 2011 Waters Corporation 1 Waters Commitment To develop, commercialize and market columns that when used on Waters ACQUITY
More informationApplied Protein Services
Applied Protein Services Applied Protein Services A Window into the Future Development risk and attrition rates remain two of the greatest challenges to a successful biopharmaceutical pipeline. To help
More information-PLEX. Immunogenicity Assay Application Note. Measuring anti-drug antibodies (ADAs) to two different drugs using a multiplex bridging assay
-PLEX Immunogenicity Assay Application Note 1 Measuring anti-drug antibodies (ADAs) to two different drugs using a multiplex bridging assay The use of biotherapeutics, biosimilars, and combination biotherapies
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationTrastuzumab Glycan Batch-to-Batch Profiling using a UPLC/FLR/Mass Spectrometry Platform
Trastuzumab Glycan Batch-to-Batch Profiling using a UPLC/FLR/Mass Spectrometry Platform Ying Qing Yu, Joomi Ahn, and Martin Gilar Waters Corporation, Milford, MA, U.S. APPLICATION BENEFITS Used together,
More informationExpectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective
Expectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective Christian Mayer AGES - Austrian Agency for Health and Food Safety Analytical Technologies Europe
More informationAB SCIEX TripleTOF 5600 SYSTEM. High-resolution quant and qual
AB SCIEX TripleTOF 5600 SYSTEM High-resolution quant and qual AB SCIEX TripleTOF 5600 SYSTEM AB SCIEX is a global leader in the development of life science analytical technologies that help answer complex
More informationThermo Scientific Proteomics & Metabolomics Seminar Tour
Proteomics & Seminar Tour Ignite your workflows with our with Cutting Edge LC-MS Technology Stop by to learn the latest advances in mass spectrometry workflows, technologies launched at 2012 ASMS and talk
More informationThe clearly better choice
Agilent Accurate-Mass 6500 Series Q-TOF and 600 Series TOF LC/MS Systems The clearly better choice in TOF and Q-TOF LC/MS Our measure is your success. products applications soft ware services The unmatched
More informationStability of Biological Products
Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth
More informationSMART Digest ImmunoAffinity (IA) Kit User Manual. Version 1
MART Digest ImmunoAffinity (IA) Kit User Manual Version 1 XX21549-EN 0816 Revision A August 2016 MART Digest ImmunoAffinity (IA) Kits Delivering Fast, imple and ighly Reproducible Immunocapture and Digestion
More informationMSD Immuno-Dot-Blot Assays. A division of Meso Scale Diagnostics, LLC.
MSD Immuno-Dot-Blot Assays Example: High Throughput Western Blots Replacements Traditional Western Blots High content Molecular weight and immunoreactivity Labor and protein intensive Inherently low throughput
More information